Product Description
For Treatment of chronic pain (Sourced from: https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Frezatomidine.pdf)
Mechanisms of Action: ADRA1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fibromyalgia|Myofascial Pain Syndromes|Cystitis, Interstitial|Pain Unspecified|Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-006100-11 |
2006-006100-11 | P2 |
Completed |
Fibromyalgia |
2009-10-27 |
2022-03-13 |
Treatments |
|
NCT00441766 |
NCT00441766 | P2 |
Terminated |
Irritable Bowel Syndrome |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00445705 |
NCT00445705 | P2 |
Terminated |
Fibromyalgia|Myofascial Pain Syndromes |
2008-01-01 |
2019-03-21 |
Treatments |
|
NCT00381719 |
NCT00381719 | P2 |
Completed |
Pain Unspecified |
2007-11-01 |
2019-03-21 |
Treatments |
|
NCT00380783 |
NCT00380783 | P2 |
Terminated |
Cystitis, Interstitial |
2007-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/28/2022 |
News Article |
Global Pain Therapeutics Market to 2029 - Featuring Abbott Laboratories, AstraZeneca and GlaxoSmithKline Among Others |